Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're about to lose access.

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

also called a Zepbound pen. The vial doses available are 2.5 mg and 5 mg, which is limited compared to the six Zepbound pen doses. Single-dose vials may be less convenient than an auto-injector pen.

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

While hardly anyone used the features, Samsung’s decision to remove remote features from the S Pen on the Galaxy S25 Ultra has been met with vocal criticism. Now, as previously confirmed ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co ... for which the company recently paid $2.5 billion. All of this is to say that, despite the massive ...

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.